Novartis and Qualcomm Life will partner on the development of Novartis’ Breezhaler inhaler device, a digital inhaler for patients suffering from COPD.
The Breezhaler inhaler will provide them compliance with the facility of accessing the data of their usage. It will consist of a device that can detect and report the usage to the patient as well as physician. The device is integrated with the patient’s smart phone and Novartis COPD mobile application.
The application will transmit the data to the company’s COPD cloud. With the help of the data, the physician will be able to monitor the extent of obstruction.The device is very easy to handle with no assembly requirement. The drug maker is planning to launch the device in 2019.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management
- Edition Archive